Furthermore, LY3484356 has displayed additivity in combination with CDK4/6 inhibitors, mTOR inhibitors, and PIK3CA inhibitors in blocking cell proliferation, as well as tumor growth inhibition in xenograft and PDX models of breast cancer. Here, CDK4 is linked to neoplasm.